166 related articles for article (PubMed ID: 31865846)
1. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
Kupsh A; Arnall J; Voorhees P
J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
[TBL] [Abstract][Full Text] [Related]
2. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
[TBL] [Abstract][Full Text] [Related]
4. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
[TBL] [Abstract][Full Text] [Related]
5. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.
Nalghranyan S; Singh AP; Schinke C
Am J Hematol; 2020 Feb; 95(2):E34-E35. PubMed ID: 31709578
[No Abstract] [Full Text] [Related]
6. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
Gonsalves WI; Buadi FK; Kumar SK
Eur J Haematol; 2018 Feb; 100(2):215-217. PubMed ID: 29064593
[TBL] [Abstract][Full Text] [Related]
7. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
Abu Zaanona MI; Patel P
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
9. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
10. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
[No Abstract] [Full Text] [Related]
11. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
[TBL] [Abstract][Full Text] [Related]
12. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
[TBL] [Abstract][Full Text] [Related]
13. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
Rahbari KJ; Nosrati JD; Spektor TM; Berenson JR
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e339-e343. PubMed ID: 30033209
[No Abstract] [Full Text] [Related]
16. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report.
Yang Y; Fu LJ; Chen CM; Hu MW
World J Clin Cases; 2021 Feb; 9(5):1175-1183. PubMed ID: 33644182
[TBL] [Abstract][Full Text] [Related]
18. Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.
Freise KJ; Jones AK; Verdugo ME; Menon RM; Maciag PC; Salem AH
Clin Pharmacol Ther; 2017 Dec; 102(6):970-976. PubMed ID: 28419431
[TBL] [Abstract][Full Text] [Related]
19. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
[TBL] [Abstract][Full Text] [Related]
20. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma.
Kambhampati S; Galligan D; Huang CY; Wong S; Wolf J; Martin T; Shah N
Leuk Lymphoma; 2020 May; 61(5):1211-1219. PubMed ID: 31928108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
